• Friday, April 13, 2018 @ 12:00 am

Swiss Biotech Startup and ETH Spinoff ProteoMediX AG announced results from a retrospective study that showed the correlation of its prostate cancer diagnosis test with cancer aggressiveness in patients scheduled for prostate biopsies. The study findings presented at the 2018 European Association of Urology (EAU) congress in Copenhagen, Denmark showed that the test has the potential to avoid a large number of biopsies.

Please find more information in the press release PDF below.

You may also be interested in